Press / Special articles

Press / Special articles » Press releases

Detailed view

Date: 31.05.2013 13:50

Successful treatment of peri-implantitis with HELBO treatment: the one-year data in comparison with local antibiotic treatment is available

The medical community is in agreement that more and more pathogens are increasingly developing resistances to antibiotics. In the context of this, HELBO treatment offers a successful alternative in the field of dentistry.

It has been common knowledge for a long time that some types of bacteria can already no longer be successfully combated, as the serious MRSA cases in the University Hospital of Freiburg and in the Elbeklinikum Hospital in Stade prove. The problem is not a new one: the Deutsche Gesellschaft für Krankenhaushygiene [German Society of Hospital Hygiene] already estimated in 2009 that around 40,000 deaths a year are caused by infections acquired in German hospitals. Bacterial infections also represent a problem for dentistry and are the most common cause of dental and implant loss. Fighting infections according to conventional methods is a major challenge - antibiotics are often the weapon of choice, despite the danger that the pathogens will develop a resistance, and even though the potential side effects are significant. In dental surgeries, opposition to antibiotic treatment is growing - even on the part of patients.
Treatment must nevertheless be carried out - but how?

The HELBO procedure represents a modern alternative. This treatment involves a minimally invasive, tissue-preserving method of infection control, which is capable of destroying the bacteria, thanks to the interaction of a light-activated dye and lopw-energy laser light with a specific wave length and energy density. This is currently confirmed by Prof. Dr. Dr. Anton Sculean, who in his latest publication "Antiinfective therapy of peri-implantitis with adjunctive local drug delivery or photodynamic therapy: 12- month outcomes of a randomized controlled clinical trial" (Journal of Clinical Oral Implants Research, Res. 00, 2013 / 1–9) demonstrates that HELBO therapy achieves good results in the treatment of periimplantar diseases, comparable to those seen with a local antibiotic – but without the side effects or the danger that the bacteria will develop resistance. This outcome is already considered groundbreaking and pioneering by dental experts.

You can find this study and many other randomised clinical trials on HELBO treatment at: PubMed: http://www.ncbi.nlm.nih.gov/pubmed. Information on HELBO treatment is available at: www.helbo.de.


The bredent group is an internationally-active, family-run company.

It develops and produces optimally coordinated stand-alone products, system solutions (e.g. in implant prosthetics) and "Made in Germany" treatment concepts. These enable dentists and dental technicians to produce and maintain high-quality, cost-effective aesthetic restorations that ensure periodontal hygiene.

The bredent group strives to be amongst the best. That is why the employees are always ready to deliver excellence for our clients and their patients, with the necessary flexibility and openness.

With its expertise and innovative drive, the bredent group is the paradigm for the dental market.



Press contact
bredent medical GmbH & Co. KG
HELBO operational division
Ulrike Vizethum
Josef-Reiert-Strasse 4
D-69190 Walldorf
Tel.: (+49) 06227/53960-0
Fax: (+49) 06227/53960-11
ulrike.vizethum@helbo.de